SRC
ALNY icon

Shufro Rose & Co’s Alnylam Pharmaceuticals ALNY Stock Holding History

Shufro Rose & Co’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,100
Closed -$261K – 322
2022
Q4 		$261K Hold
1,100
– – 0.02% 260
2022
Q3 		$220K Buy
+1,100
New +$210K 0.02% 263

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Shufro Rose & Co's ALNY Position: Q1 2023 in Review

Shufro Rose & Co sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 1,100 shares — an estimated $261K sold.

Shufro Rose & Co first reported a position in ALNY in Q3 2022 and held it in 2 quarters. The position peaked at $261K in Q4 2022. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

  • Shufro Rose & Co reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Shufro Rose & Co sold 1,100 Alnylam Pharmaceuticals shares in Q1 2023, an estimated $261K.
  • Shufro Rose & Co first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • Shufro Rose & Co's Alnylam Pharmaceuticals position peaked at $261K in Q4 2022.
  • 477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on Shufro Rose & Co's 13F filing for Q1 2023, filed 20 Apr 2023.